The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Completed

• Conditions: HIV Positive; Opioid Dependence; Opioid Agonist Treatment; HIV Infections

• Registration Number: NCT00857350
• Lead Sponsor: Yale University

Brief Summary

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses:

1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.

2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2009-03-04
• Study First Submitted QC: 2009-03-05
• Study First Posted: 2009-03-06
• Primary Completion: 2010-06
• Study Completion: 2012-09
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-19
• Last Update Posted: 2013-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• HIV+
• Opioid dependent
• Receiving methadone or buprenorphine for at least one month

Read More

Exclusion Criteria

• age < 18 years
• current dementia;
• inability to read or understand English
• inability to provide written informed consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HIV drug resistance	Cross sectional

Secondary Outcome Measures

Name	Time	Method
Illicit drug use	6 months
HIV transmission risk behaviors	1 year

Trial Locations

Locations (1)

Yale University Hospital; 🇺🇸 New Haven, Connecticut, United States